Silverback Therapeutics   Report issue

For profit Phase 2
Founded: Seattle WA United States (2016)
Status: Acquired by ARS Pharmaceuticals, Inc. (2022)

Organization Overview

First Clinical Trial
2020
NCT04460456
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Silverback Therapeutics | Silverback Therapeutics, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 7